Dr Chantal Bader
About
Chantal Bader studied Pharmacy at the Ruprecht-Karls-University Heidelberg, Germany (Approbation as Pharmacist, 2016). In 2016, she the department of Rolf Müller at HIPS. Working on the isolation and characterization of natural products from myxobacteria, she obtained her masters and later on Ph.D. degree here. Supported by the DFG Walter-Benjamin-Fellowship, she moved to the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (Florida, US, 2022), where she joined Prof. Shens group. As leader of function-guided screenings of the extensive extract library here, she expanded her focus towards discovery of anti-Gram-negative antibiotics and antiplasmodials from actinobacteria. In July 2024, Chantal joined HIPS again as pilot of the Young AcademiXX program.
Chantal’s research focuses on elucidation of uncharacterized natural products with emphasis on antiparasitics and their application for the treatment of neglected tropical diseases. She is particularly interested in the ecological context under which these pharmaceutically relevant natural products are produced and deciphering signaling molecules secreted by taxonomically distant organisms to induce their production. For her outstanding achievements as part of her doctorate, she has been awarded by the HZI Sponsors’ Association and the Hans-und-Ruth-Giessen-Foundation, among others.
2024
Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism
Garcia R, Popoff A, Bader C, Löhr J, Walesch S, Walt C, Boldt J, Bunk B, Haeckl F, Gunesch A, …, Bach T, Müller R (2024)
Chem 10: 1-20DOI: 10.1016/j.chempr.2024.04.019
Elucidation of unusual biosynthesis and DnaN-targeting mode of action of potent anti-tuberculosis antibiotics Mycoplanecins
Fu C, Liu Y, Walt C, Rasheed S, Bader C, Lukat P, Neuber M, Haeckl F, Blankenfeldt W, Kalinina O, Müller R (2024)
Nat Commun 15 (1)DOI: 10.1038/s41467-024-44953-5
2023
Genome-Guided Discovery of the Myxobacterial Thiolactone-Containing Sorangibactins
Gao Y, Walt C, Bader C, Müller R (2023)
ACS chemical biology 18 (4): 924-932DOI: 10.1021/acschembio.3c00063
2022
Darobactins Exhibiting Superior Antibiotic Activity by Cryo-EM Structure Guided Biosynthetic Engineering
Seyfert C, Porten C, Yuan B, Deckarm S, Panter F, Bader C, Coetzee J, Deschner F, Tehrani K, Higgins P, …, Herrmann J, Müller R (2022)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202214094
Large-Scale Interlaboratory DI-FT-ICR MS Comparability Study Employing Various Systems
Forcisi S, Moritz F, Thompson C, Kanawati B, Uhl J, Afonso C, Bader C, Barsch A, Boughton B, Chu R, …, Laukien F, Schmitt-Kopplin P (2022)
Journal of the American Society for Mass SpectrometryDOI: 10.1021/jasms.2c00082
Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA
Fathalla R, Fröhner W, Bader C, Fischer P, Dahlem C, Chatterjee D, Mathea S, Kiemer A, Arthanari H, Müller R, …, Ducho C, Engel M (2022)
Journal of medicinal chemistryDOI: 10.1021/acs.jmedchem.2c01275
Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors
Haack P, Harmrolfs K, Bader C, Garcia R, Gunesch A, Haid S, Popoff A, Voltz A, Kim H, Bartenschlager R, Pietschmann T, Müller R (2022)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202212946
Sandacrabins - Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium
Bader C, Panter F, Garcia R, Tchesnokov E, Haid S, Walt C, Spröer C, Kiefer A, Götte M, Overmann J, Pietschmann T, Müller R (2022)
Chem. Eur. J. 28 (10)DOI: 10.1002/chem.202104484
2021
Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering
Groß S, Panter F, Pogorevc D, Seyfert C, Deckarm S, Bader C, Herrmann J, Müller R (2021)
Chem. Sci. 12 (35): 11882-11893DOI: 10.1039/d1sc02725e
Sesbanimide R, a Novel Cytotoxic Polyketide Produced by Magnetotactic Bacteria
Awal R, Haack P, Bader C, Riese C, Schüler D, Müller R (2021)
mBio 12 (3)DOI: 10.1128/mBio.00591-21
Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity
Ropponen H, Bader C, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch A (2021)
ChemMedChem 16 (13): 2089-2093DOI: 10.1002/cmdc.202100067
Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics
Panter F, Bader C, Müller R (2021)
Chem. Sci. 12 (17): 5994-6010DOI: 10.1039/d0sc06919a
The Sandarazols are Cryptic and Structurally Unique Plasmid-Encoded Toxins from a Rare Myxobacterium*
Panter F, Bader C, Müller R (2021)
Angewandte Chemie (International ed. in English) 60 (15): 8081-8088DOI: 10.1002/anie.202014671
Expanding the Scope of Detectable Microbial Natural Products by Complementary Analytical Methods and Cultivation Systems
Bader C, Haack P, Panter F, Krug D, Müller R (2021)
Journal of natural products 84 (2): 268-277DOI: 10.1021/acs.jnatprod.0c00942
2020
Supercritical Fluid Extraction Enhances Discovery of Secondary Metabolites from Myxobacteria
Bader C, Neuber M, Panter F, Krug D, Müller R (2020)
Analytical chemistry 92 (23): 15403-15411DOI: 10.1021/acs.analchem.0c02995
In depth natural product discovery - Myxobacterial strains that provided multiple secondary metabolites
Bader C, Panter F, Müller R (2020)
Biotechnol Adv 39DOI: 10.1016/j.biotechadv.2019.107480
2019
Synthesis of New Cyclomarin Derivatives and Their Biological Evaluation towards Mycobacterium Tuberculosis and Plasmodium Falciparum
Kiefer A, Bader C, Held J, Esser A, Rybniker J, Empting M, Müller R, Kazmaier U (2019)
Chem. Eur. J. 25 (37): 8894-8902DOI: 10.1002/chem.201901640
Engineering Atypical Tetracycline Formation in Amycolatopsis sulphurea for the Production of Modified Chelocardin Antibiotics
Lukežic T, Fayad A, Bader C, Harmrolfs K, Bartuli J, Groß S, Lešnik U, Hennessen F, Herrmann J, Pikl Š, Petkovic H, Müller R (2019)
ACS Chem. Biol. 14 (3): 468-477DOI: 10.1021/acschembio.8b01125
2018
Concepts and Methods to Access Novel Antibiotics from Actinomycetes
Hug J, Bader C, Remškar M, Cirnski K, Müller R (2018)
Antibiotics 7 (2)DOI: 10.3390/antibiotics7020044